Ensartinib (Ensacove) is now the first-line treatment for adults with ALK-positive non-small-cell lung cancer (NSCLC). This new drug targets the abnormal fusion proteins that drive the growth and spread of cancer cells in this specific type of lung cancer.
a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC). Sold under the brand name Ensacove , this drug is now a first-choice treatment for people with this type of cancer. It is for patients whose cancer has either grown nearby or spread to other parts of the body and who haven’t been treated with an ALK-blocking drug before. ALK-positive NSCLC is frequently diagnosed in younger people with little to no history of smoking.
It arises from certain changes in the ALK gene that produce abnormal fusion proteins, promoting growth and spread of cancer cells. ALK-positive NSCLC makes up about 3% to 11% of all lung cancer cases and is often more aggressive, with a higher chance of coming back after treatment and worse results. This highlights the need for specific drugs that can stop the effects of these abnormal fusion proteins. Ensartinib is a new second-generation ALK inhibitor that blocks the activity of faulty ALK proteins by preventing their access to energy molecules within cancer cells. In this way, ensartinib disrupts the signals that help cancer cells grow, reduces tumor growth, and leads to cancer cell death. Developed jointly by Xcovery and Betta Pharmaceuticals, this once-daily oral drug is designed to overcome the shortcomings of current therapies and improve outcomes in patients with ALK-positive NSCLC. The approval was based on promising results from a clinical trial that assessed the effectiveness of ensartinib versus crizotinib (a first-generation ALK inhibitor) in 290 patients with advanced ALK-positive NSCLC who had not previously received any ALK inhibitor therapy. Patients were randomly assigned to receive either ensartinib or crizotinib. Results showed that ensartinib significantly improved progression-free survival, with patients living for about 25.8 months on average without their cancer worsening; in contrast, those taking crizotinib lived for about 1
ALK-Positive NSCLC Ensartinib Ensacove Lung Cancer New Drug Cancer Treatment
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Bizengri for NSCLC and Pancreatic Cancers Harboring NRG1 Gene FusionThe systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.
Read more »
New York City's minimum wage is set to go up New Year's Day — but some say it's not nearlyWith a new year comes new opportunities for New Yorkers making the minimum wage.
Read more »
FDA Approves New Drug for Lung and Pancreatic CancersThe FDA has granted accelerated approval to zenocutuzumab, a new drug for adults with advanced non-small-cell lung cancer (NSCLC) or pancreatic cancer.
Read more »
New England Patriots Could Take Full Advantage of Jets DownfallThe New England Patriots should monitor a massive trade option with the New York Jets.
Read more »
Former New York Knicks Guard to Make MSG Network DebutA new voice will debut on the New York Knicks' airwaves this week.
Read more »
New ship, Disney Treasure, christened in New York Harbor with dazzling drone showThe newest ship, the Disney Treasure, took part in an important maritime tradition: getting christened in New York Harbor with a dazzling drone show.
Read more »